Medicine and Dentistry
Acute Coronary Syndrome
13%
Acute Heart Infarction
16%
Adverse Event
12%
All Cause Mortality
10%
Amino Terminal Sequence
7%
Angiography
9%
Anticoagulation
7%
Antithrombotic
9%
Aortic Insufficiency
7%
Aortic Stenosis
67%
Aortic Valve
16%
Aortic Valve Replacement
24%
Aortic Valve Stenosis
9%
Apoplexy
33%
Arteriosclerosis Obliterans
7%
Atrial Fibrillation
10%
Bicuspid Aortic Valve
7%
Biological Marker
8%
Bleeding
12%
Brain Natriuretic Peptide
22%
Cardiac Magnetic Resonance Imaging
13%
Cardiac Resynchronization Therapy
9%
Cardiology
21%
Cardiovascular Disease
20%
Cardiovascular Imaging
7%
Cardiovascular Risk
12%
Cardiovascular System
19%
Chronic Total Occlusion
19%
Clinical Trial
10%
Combination Therapy
8%
Comorbidity
8%
Computed Tomography Angiography
13%
Computer Assisted Tomography
10%
Congestive Heart Failure
63%
Coronary Angiography
19%
Coronary Artery Aneurysm
13%
Coronary Artery Disease
23%
Defibrillator
18%
Diagnosis
15%
Diagnostic Error
7%
Diseases
21%
Dobutamine
9%
Echocardiography
18%
Ejection Fraction
17%
EuroSCORE
10%
Geriatrics
13%
Hazard Ratio
12%
Health Care Cost
7%
Heart Amyloidosis
19%
Heart Atrium Pacing
8%
Heart Failure with Preserved Ejection Fraction
13%
Heart Left Ventricle Ejection Fraction
13%
Heart Surgery
14%
Heart Valve
7%
Heart Ventricle Remodeling
7%
Hemodynamic
12%
Hospital Mortality
16%
Hypervolemia
23%
Impedance Spectroscopy
8%
Implantable Automatic Defibrillator
21%
In Vitro
8%
Kaplan Meier Method
11%
Long-Term Care
13%
Magnetic Resonance Imaging
15%
Meta-Analysis
52%
Mitral Insufficiency
20%
Mitral Valve Repair
13%
Mortality Rate
8%
Myocardial Infarction
13%
National Inpatient Sample
13%
Natriuretic Factor
8%
Nephrologist
7%
Non ST Segment Elevation Myocardial Infarction
8%
Odds Ratio
12%
Patient Referral
7%
Percutaneous Aortic Valve Replacement
100%
Percutaneous Coronary Intervention
21%
Placebo
9%
Pooled Analysis
13%
Prevalence
28%
Primary Percutaneous Coronary Intervention
7%
Proportional Hazards Model
7%
Pulmonary Artery
9%
Pulmonary Hypertension
11%
Quality of Life
9%
Randomized Controlled Trial
9%
Retrospective Cohort Study
7%
Revascularization
13%
Sex Difference
8%
Systematic Review
59%
Technetium-99
10%
Thorax Pain
9%
Thromboembolism
13%
Thrombus
7%
Tricuspid Insufficiency
11%
Valve Replacement
10%
Valvular Heart Disease
24%
Valvuloplasty
7%
Ventricular Fibrillation
8%
Ventricular Tachycardia
13%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Coronary Syndrome
6%
Acute Heart Infarction
7%
Acute Kidney Failure
6%
Adverse Device Effect
6%
Adverse Event
9%
Angiotensin
6%
Angiotensin I
6%
Aortic Stenosis
13%
Aortic Valve Stenosis
6%
Atorvastatin
6%
Atrial Fibrillation
9%
Biological Marker
6%
Cardiogenic Shock
6%
Cause of Death
6%
Cerebrovascular Accident
14%
Chronic Total Occlusion
19%
Cluster Randomized Trial
6%
Clusterin
6%
Cohort Study
8%
Congestive Heart Failure
21%
Coronary Artery Aneurysm
6%
Coronary Artery Disease
7%
Disease
5%
Dobutamine
6%
Empagliflozin
10%
End Stage Renal Disease
6%
Ertugliflozin
6%
Heart Amyloidosis
13%
Heart Failure with Preserved Ejection Fraction
6%
Heart Failure with Reduced Ejection Fraction
5%
Heart Infarction
7%
Heart Injury
7%
Heart Ventricle Arrhythmia
6%
Heart Ventricle Tachycardia
6%
High Density Lipoprotein
6%
Hormone Precursor
5%
Hospital Mortality
7%
Hypertensive Factor
6%
Hypervolemia
16%
Interleukin 6
6%
Ivabradine
6%
Kidney Artery Stenosis
6%
Low Density Lipoprotein Cholesterol
6%
Membrane Metalloendopeptidase
7%
Mycosis
6%
Myocarditis
6%
Non ST Segment Elevation Myocardial Infarction
7%
Peripheral Occlusive Artery Disease
7%
Placebo
9%
Prevalence
26%
Prospective Cohort Study
6%
Prosthetic Valve Dysfunction
6%
Pulmonary Hypertension
13%
Riociguat
6%
Rosuvastatin
6%
Sodium Glucose Cotransporter 2 Inhibitor
7%
South American Blastomycosis
6%
ST Segment Elevation Myocardial Infarction
7%
Syndrome
6%
Thorax Pain
6%
Thrombus
6%
Transthyretin
6%
Valvular Heart Disease
6%
Venous Thromboembolism
6%
Virus Infection
6%
Vitamin K Group
6%